OCULAR THERAPEUTIX, INC
OCULNasdaq
$8.97
↓ -2.1%Jul 17 close · end-of-day
Price
1Y↓ -20.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.0B
Enterprise Value
$1.3B
P/E
—
P/S
38.6
P/B
3.5
EV/EBITDA
—
PEG
—
FCF Yield
-12.0%
Dividend Yield
—
Revenue (TTM)
$52.0M
Net Income (TTM)
-$290.5M
Free Cash Flow (TTM)
-$240.9M
Gross Margin
—
Operating Margin
-575.4%
Net Margin
-558.2%
ROE
-50.0%
ROIC
—
Debt / Equity
—
Net Cash
$666.7M
Return 1Y
-21.2%
Company profile
Ocular Therapeutix, Inc. focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases.
- CEO
- Antony Mattessich
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 230
- Headquarters
- Massachusetts
- Website
- ocutx.com
Management & directors
- Dugel PravinSee Remarks
- Robins Jason ShandChief Financial Officer
- Waheed NadiaChief Medical Officer
- Heier Jeffrey S.Chief Scientific Officer
- Kaiser PeterChief Development Officer
- Nayak SanjayChief Strategy Officer
- Notman DonaldChief Operating Officer
- Robinson David WayneGlobal CCO
- Anderman ToddChief Legal Officer
- Meyers Steve LawrenceChief Commercial Officer
- Saroj NamrataChief Business Officer
Roles derived from SEC Form 4 filings.
Earnings
OCUL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$10.8M↑ +0.8%
Diluted EPS-$0.40↑ +5.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $17.4M | $43.5M | $51.5M | $58.4M | $63.7M | $52.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$62.8M | -$78.0M | -$78.7M | -$82.4M | -$171.8M | -$270.0M |
| Net income | -$155.6M | -$6.6M | -$71.0M | -$80.7M | -$193.5M | -$265.9M |
| Diluted EPS | -$2.56 | -$0.98 | -$0.97 | -$1.02 | -$1.22 | -$1.42 |
| Operating cash flow | -$53.6M | -$65.5M | -$59.6M | -$70.2M | -$134.7M | -$204.9M |
| Free cash flow | -$54.4M | -$66.7M | -$63.3M | -$76.3M | -$136.0M | -$216.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -361.1% | -179.3% | -152.7% | -141.0% | -269.6% | -519.8% |
| Net margin | -894.3% | -15.1% | -138.0% | -138.1% | -303.7% | -511.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.4M | $15.4M | $17.1M | $10.7M | $13.5M | $14.5M | $13.3M | $10.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$43.6M | -$46.0M | -$50.6M | -$63.9M | -$67.6M | -$68.7M | -$69.8M | -$93.3M |
| Net income | -$43.8M | -$36.5M | -$48.4M | -$64.1M | -$67.8M | -$69.4M | -$64.7M | -$88.6M |
| Diluted EPS | -$0.26 | -$0.22 | -$0.25 | -$0.38 | -$0.39 | -$0.38 | -$0.27 | -$0.40 |
| Operating cash flow | -$24.8M | -$36.6M | -$39.4M | -$44.7M | -$55.2M | -$50.7M | -$54.2M | -$66.0M |
| Free cash flow | -$25.5M | -$36.6M | -$39.6M | -$46.6M | -$56.5M | -$56.7M | -$57.1M | -$70.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -265.1% | -298.2% | -296.1% | -597.5% | -502.6% | -472.3% | -526.5% | -865.5% |
| Net margin | -266.3% | -236.6% | -283.3% | -598.7% | -503.9% | -477.3% | -488.0% | -821.6% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-16 | Dugel Pravin· See Remarks | Gift | 50,092 | $0.00 | $0.00 | filing |
| 2026-06-16 | Dugel Pravin· See Remarks | Gift | 50,092 | $0.00 | $0.00 | filing |
| 2026-06-10 | Warden Charles M | Award | 14,000 | $0.00 | $0.00 | filing |
| 2026-06-10 | Graves Adrienne L | Award | 14,000 | $0.00 | $0.00 | filing |
| 2026-06-10 | Robins Jason Shand· Chief Financial Officer | Award | 15,441 | $0.00 | $0.00 | filing |
| 2026-06-10 | Hong Seung Suh | Award | 14,000 | $0.00 | $0.00 | filing |
| 2026-06-10 | LINDSTROM RICHARD L MD | Award | 14,000 | $0.00 | $0.00 | filing |
| 2026-06-10 | RAINES MERILEE | Award | 14,000 | $0.00 | $0.00 | filing |
| 2026-06-10 | Williams Leslie J. | Award | 14,000 | $0.00 | $0.00 | filing |
| 2026-06-03 | Waheed Nadia· Chief Medical Officer | Sale | 14,828 | $8.27 | $122,627.56 | filing |
| 2026-05-28 | Dugel Pravin· See Remarks | Gift | 394,696 | $0.00 | $0.00 | filing |
| 2026-05-28 | Dugel Pravin· See Remarks | Gift | 394,696 | $0.00 | $0.00 | filing |
| 2026-05-26 | Dugel Pravin· See Remarks | Sale | 21,156 | $8.20 | $173,479.20 | filing |
| 2026-05-26 | Heier Jeffrey S.· Chief Scientific Officer | Sale | 3,018 | $8.20 | $24,747.60 | filing |
| 2026-05-26 | Kaiser Peter· Chief Development Officer | Sale | 2,967 | $8.20 | $24,329.40 | filing |
| 2026-05-26 | Nayak Sanjay· Chief Strategy Officer | Sale | 1,858 | $8.20 | $15,235.60 | filing |
| 2026-04-09 | Dugel Pravin· See Remarks | Gift | 394,696 | $0.00 | $0.00 | filing |
| 2026-04-09 | Dugel Pravin· See Remarks | Gift | 394,696 | $0.00 | $0.00 | filing |
| 2026-02-23 | Dugel Pravin· See Remarks | Sale | 20,056 | $8.28 | $166,063.68 | filing |
| 2026-02-23 | Heier Jeffrey S.· Chief Scientific Officer | Sale | 3,057 | $8.28 | $25,311.96 | filing |
| 2026-02-23 | Kaiser Peter· Chief Development Officer | Sale | 2,810 | $8.28 | $23,266.80 | filing |
| 2026-02-23 | Nayak Sanjay· Chief Strategy Officer | Sale | 1,759 | $8.28 | $14,564.52 | filing |
| 2026-02-20 | LINDSTROM RICHARD L MD | Buy | 60,229 | $7.66 | $461,354.14 | filing |
| 2026-02-20 | Waheed Nadia· Chief Medical Officer | Sale | 3,510 | $7.74 | $27,167.40 | filing |
| 2026-02-12 | Dugel Pravin· See Remarks | Sale | 124,882 | $9.04 | $1.1M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.